Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, February 19:Nova Ltd. (NVMI) : This semiconductor equipment company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.3% over the last 60 days.Nova's shares gained 56.8% over the last three months compared with the S&P 500’s advanced of 3.5%. The company possesses a Momentum Score of A.Freshworks Inc. (FRSH) : This software development company has a ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:GE Aerospace (GE) : This manufacturer of aircraft engines, components and aircraft mechanical systems has seen the Zacks Consensus Estimate for its current year earnings increasing 3.9% over the last 60 days.Oportun Financial Corporation (OPRT) : This financial services provider has seen the Zacks Consensus Estimate for its current year earnings increasing 9.2% over the last 60 days.enGene Holdings Inc. (ENGN) : This clinical-stage biot ...

Shares of enGene Holdings Inc. (ENGN) have gained 8% over the past four weeks to close the last trading session at $8.10, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $27.44 indicates a potential upside of 238.8%.The average comprises nine short-term price targets ranging from a low of $16 to a high of $37, with a standard deviation of $7.38. While the lowest estimate indicat ...

enGene Holdings Inc. (ENGN) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by t ...

enGene Holdings (NASDAQ: ENGN ) is a biotech focused mainly on the development of gene therapies, with their first shot on goal being in specific forms of bladder cancer. Through the use of plasmid technology, the company hopes to demonstrate that non-viralI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due dili ...

Group 1 - enGene Holdings Inc. (ENGN) has experienced a significant decline of 16.9% over the past four weeks, but it is now positioned for a potential trend reversal as it is in oversold territory [1] - The Relative Strength Index (RSI) for ENGN is currently at 26.43, indicating that the heavy selling pressure may be exhausting itself, suggesting a possible reversal in the stock's trend [4] - There is strong consensus among Wall Street analysts that ENGN will report better earnings than previously predicted, with a 2.3% increase in the consensus EPS estimate over the last 30 days [5] Group 2 - ENGN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for price appreciation in the near term [5]

Pivotal phase 2 LEGEND study of EG-70 in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) remains on track with interim data anticipated in mid-2024 Closed a $200 million oversubscribed private financing, expected to extend cash runway into 2027 BOSTON and MONTREAL, March 11, 2024 /PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unre ...

Financing included participation from new and existing investors Pro forma cash and cash equivalents expected to fund current operating plan into 2027 BOSTON and MONTREAL, Feb. 14, 2024 /PRNewswire/ - enGene Holdings Inc. (Nasdaq: ENGN or "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral lead program EG-70 is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced that it has agreed to sell 20 million of its common shares at a ...

Experienced biotech executive brings public company expertise in legal, corporate governance, and compliance to support enGene during late-stage clinical development and anticipated future commercial launch of its lead program EG-70 BOSTON and MONTREAL, Jan. 30, 2024 /PRNewswire/ - enGene Holdings Inc. ("enGene," (Nasdaq: ENGN), a clinical-stage genetic medicines company whose lead program is in a pivotal study for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), today announced the appointment ...

Achieved primary and secondary endpoints in Phase 1 portion of LEGEND study in non-muscle invasive bladder cancer (NIMBC); pivotal portion underway with interim data expected mid this year Completed a reverse merger transaction with Forbion European Acquisition Corp (FEAC), launched as a public company on November 1, 2023, and completed an upsized PIPE financing Combined transactions resulted in net proceeds of approximately $109 million Closed an expanded $50M debt facility with Hercules Capital in Decembe ...